ALTIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.395 USD | -11.91% |
|
-15.52% | -43.16% |
| 04-29 | Altimmune Shares Decline After Guggenheim Downgrade | MT |
| 04-29 | Guggenheim Downgrades Altimmune to Neutral From Buy | MT |
| Sales 2024 * | 41.67M 3.32B | Sales 2025 * | 33.33M 2.65B | Capitalization | 515M 40.98B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.7B | Net income 2025 * | -158M -12.58B | EV / Sales 2024 * | 10.1 x |
| Net cash position 2024 * | 91.94M 7.32B | Net cash position 2025 * | 285M 22.67B | EV / Sales 2025 * | 6.9 x |
| P/E ratio 2024 * |
-7.7
x | P/E ratio 2025 * |
-4.78
x | Employees | 59 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Altimmune, Inc.
More recommendations
More press releases
More news
| 1 day | -11.91% | ||
| 1 week | -15.52% | ||
| Current month | -37.18% | ||
| 1 month | -37.49% | ||
| 3 months | -34.74% | ||
| 6 months | +167.57% | ||
| Current year | -43.16% |
1 week
6.28
7.75
1 month
6.2811.01
Current year
6.2814.84
1 year
2.0914.84
3 years
2.0923.49
5 years
1.5135.10
10 years
1.51237.30
| Managers | Title | Age | Since |
|---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 29/11/18 |
| Director of Finance/CFO | 66 | 30/12/21 | |
Anthony Blandin
CMP | Compliance Officer | - | 31/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 31/03/10 |
Mack Gill
BRD | Director/Board Member | 72 | 31/07/04 |
Philip Hodges
BRD | Director/Board Member | 56 | 31/08/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 7.26 | +0.83% | 2,250,760 |
| 25/04/24 | 7.2 | +1.69% | 2,316,111 |
| 24/04/24 | 7.08 | -6.47% | 2,205,337 |
| 23/04/24 | 7.57 | +1.34% | 3,131,602 |
Delayed Quote Nasdaq, April 29, 2024 at 09:00 pm
More quotes
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
7.26
USD
Average target price
21.86
USD
Spread / Average Target
+201.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.16% | 515M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- ALT Stock
